Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Novartis AG ADR (NYSE: NVS) closed at $121.8 down -1.32% from its previous closing price of $123.43. In other words, the price has decreased by -$1.32 from its previous closing price. On the day, 2.58 million shares were traded. NVS stock price reached its highest trading level at $123.91 during the session, while it also had its lowest trading level at $121.57.
Ratios:
For a deeper understanding of Novartis AG ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 23.70 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.75. For the most recent quarter (mrq), Quick Ratio is recorded 0.68 and its Current Ratio is at 0.88. In the meantime, Its Debt-to-Equity ratio is 0.72 whereas as Long-Term Debt/Eq ratio is at 0.55.
On August 08, 2025, Morgan Stanley Upgraded its rating to Equal-Weight which previously was Underweight but kept the price unchanged to $123.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 23 ’25 when Marshall Fiona bought 15,000 shares for $112.68 per share.
Kowalski Robert William bought 1,212 shares of NVS for $137,297 on Apr 30 ’25.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVS now has a Market Capitalization of 238339735552 and an Enterprise Value of 257277804544. As of this moment, Novartis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.61, and their Forward P/E ratio for the next fiscal year is 13.17. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.95. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.24 while its Price-to-Book (P/B) ratio in mrq is 5.27. Its current Enterprise Value per Revenue stands at 4.564 whereas that against EBITDA is 11.24.
Stock Price History:
The Beta on a monthly basis for NVS is 0.60, which has changed by 0.12361622 over the last 52 weeks, in comparison to a change of 0.20772064 over the same period for the S&P500. Over the past 52 weeks, NVS has reached a high of $133.55, while it has fallen to a 52-week low of $96.06. The 50-Day Moving Average of the stock is -4.50%, while the 200-Day Moving Average is calculated to be 4.87%.
Shares Statistics:
For the past three months, NVS has traded an average of 1.45M shares per day and 1832390 over the past ten days. A total of 1.92B shares are outstanding, with a floating share count of 1.90B. Insiders hold about 0.01% of the company’s shares, while institutions hold 7.09% stake in the company. Shares short for NVS as of 1760486400 were 4348833 with a Short Ratio of 3.00, compared to 1757894400 on 4274039. Therefore, it implies a Short% of Shares Outstanding of 4348833 and a Short% of Float of 0.22.
Dividends & Splits
According to the company, the forward annual dividend rate for NVS is 3.87, from 3.862 in the trailing year. Against a Trailing Annual Dividend Yield of 0.03128899. The stock’s 5-year Average Dividend Yield is 3.61. The current Payout Ratio is 55.42% for NVS, which recently paid a dividend on 2025-03-12 with an ex-dividend date of 2025-03-12. Stock splits for the company last occurred on 2019-04-09 when the company split stock in a 1116:1000 ratio.
Earnings Estimates
Its stock is currently analyzed by 2.0 different market analysts.
Analysts are recommending an EPS of between $9.3 and $8.81 for the fiscal current year, implying an average EPS of $8.96. EPS for the following year is $9.18, with 7.0 analysts recommending between $9.49 and $8.91.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $13.66B this quarter.It ranges from a high estimate of $13.83B to a low estimate of $13.6B. As of. The current estimate, Novartis AG ADR’s year-ago sales were $13.15BFor the next quarter, 5 analysts are estimating revenue of $13.6B. There is a high estimate of $13.6B for the next quarter, whereas the lowest estimate is $13.6B.
A total of 13 analysts have provided revenue estimates for NVS’s current fiscal year. The highest revenue estimate was $57.96B, while the lowest revenue estimate was $54.72B, resulting in an average revenue estimate of $55.39B. In the same quarter a year ago, actual revenue was $50.32BBased on 13 analysts’ estimates, the company’s revenue will be $56.83B in the next fiscal year. The high estimate is $60.66B and the low estimate is $54.19B.
